← Leaderboards
Noah M Hahn
Johns Hopkins University
$3,167,009
Attributed
$3,167,009
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $656.8K · FY2019–24$1M$750K$500K$250K$0
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$3,167,009 · 1
By mechanism
R01$3,167,009 · 1
Top collaborators
No co-investigators on record.
Most similar at Johns Hopkins University
Same institution · by research overlap
- David Monty Berman$2,271,059
- Byron H Lee$2,062,428
- William Ramses Bishai$43,237,711
- Mark Schoenberg$649,939
- Vincent W. Yang$29,529,911
Others in their field
Other Emerging Leaders on “Combination Immunotherapy”
- Gautam (george) Mitra · Leidos Biomedical Research, Inc.$39,889,328
- Stacey Lynn Clardy · Utah State Higher Education System--University Of Utah$15,144,108
- Barbara Burtness · Yale University$11,871,804
- Wilton B Williams · Duke University$11,389,307
- John Otridge · Leidos Biomedical Research, Inc.$8,845,576
- Sandhya Vasan · Henry M. Jackson Fdn For The Adv Mil/Med$7,776,394
Research focus
Combination ImmunotherapyAftercareAlternative TherapiesAcuteAntigen-Specific T CellsAttenuatedBacillus Calmette-Guerin TherapyBcg LiveAntigensAdaptive Immune ResponseBladder NeoplasmBladder Transitional Cell CarcinomaBlood SpecimenCancer PatientCd8-Positive T-LymphocytesCellsCell SurfaceCheckpoint TherapyClinical EfficacyClinical PracticeClinical TrialsBladderClone CellsCombined Modality Therapy
Grant awards (6)
Phase 1/2 Study of Modern Immunotherapy in BCG-Relapsing Urothelial Carcinoma of the Bladder - (ADAPT-BLADDER)$243,567
R01 · FY2024 · CA · contact PI
Phase 1/2 Study of Modern Immunotherapy in BCG-Relapsing Urothelial Carcinoma of the Bladder - (ADAPT-BLADDER)$597,082
R01 · FY2023 · CA · contact PI
Phase 1/2 Study of Modern Immunotherapy in BCG-Relapsing Urothelial Carcinoma of the Bladder - (ADAPT-BLADDER)$628,148
R01 · FY2022 · CA · contact PI
Phase 1/2 Study of Modern Immunotherapy in BCG-Relapsing Urothelial Carcinoma of the Bladder - (ADAPT-BLADDER)$384,580
R01 · FY2021 · CA · contact PI
Phase 1/2 Study of Modern Immunotherapy in BCG-Relapsing Urothelial Carcinoma of the Bladder - (ADAPT-BLADDER)$656,816
R01 · FY2020 · CA · contact PI
Phase 1/2 Study of Modern Immunotherapy in BCG-Relapsing Urothelial Carcinoma of the Bladder - (ADAPT-BLADDER)$656,816
R01 · FY2019 · CA · contact PI